SL-172154 for Ovary Cancer

Recruiting · 18+ · Female · Grand Rapids, MI

This study is evaluating whether a drug may help treat ovarian cancer.

See full description

About the trial for Ovary Cancer

Eligible Conditions
Primary Peritoneal Carcinoma · Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Fallopian Tubes Cancer · Ovarian Cancer

Treatment Groups

This trial involves 2 different treatments. SL-172154 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for female patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Subjects who are refractory or intolerant to existing therapies and who have received platinum-based therapies are eligible for this study show original
Patients should not be considered primary platinum refractory if they experience progression during or within one month of starting platinum-based therapy. show original
The subject is 18 years or older. show original
The person has a good health status and is able to carry out normal daily activities. show original
Has a life expectancy of more than 12 weeks. show original
Functioning organs are necessary for a person's overall health. show original
This person has a disease that can be measured using RECIST v1.1, as determined by radiologic assessment. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Approximately 24 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Approximately 24 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether SL-172154 will improve 2 primary outcomes and 10 secondary outcomes in patients with Ovary Cancer. Measurement will happen over the course of From Day 1 to 90 days after Last Dose of SL-172154.

Maximum Tolerated Dose (MTD) of SL-172154
Defined based on the rate of dose limiting toxicities (DLTs)
Safety profile of SL-172154
Incidence of all treatment emergent adverse events
Establish the recommended Phase 2 dose (RP2D) for SL-172154
Establish the RP2D for SL-172154
Assess preliminary evidence of anti-tumor activity of SL-172154
Disease assessment per investigator assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Maximum serum concentration (Cmax) of SL-172154
The Cmax is the maximum observed serum concentration of SL-172154 following single and multiple doses
Immunogenicity to SL-172154
Number and proportion of participants with positive anti-drug antibody titer
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for ovary cancer?

The most common treatments for ovarian cancer are laparotomy, radical surgery, radiotherapy, and systemic chemotherapy. There is a high rate of progression from stage II to an advanced stage in early diagnosis, so the patients are most likely to benefit from systemic chemotherapy, which achieves a good prognosis. Overexpression or over-production of the p53 protein could be an independent prognostic factor for ovarian cancer.

Anonymous Patient Answer

What are the signs of ovary cancer?

Ovary cancer does not usually present itself with severe or permanent symptoms. The possibility of an underlying ovarian disorder should always be considered when diagnosing ovarian cancer. In terms of symptomatic diagnosis the following signs should be noted: abdominal pain or tenderness, bloating, vaginal bleeding, enlarged cervical lymph nodes and pelvic swelling due to ascites (i.e. ascites and hydrothorax) are suggestive of an ovarian abnormality.

Anonymous Patient Answer

How many people get ovary cancer a year in the United States?

Around 7,300 new cases of [ovarian cancer]( will be diagnosed this year, of which 2,700 will be diagnosed in women aged 55 or over in the United States. This makes up 4.3% of breast cancer cases in women aged 55 or older in the US, a figure which is similar to that for cervical lymphoprosopa, lung cancer and malignant melanoma in women in the same age group. Ovary cancer continues to present a significant health care burden both locally and nationally, and the rate of progress in the management of ovarian cancer is hindered by a lack of education about this disease.

Anonymous Patient Answer

Can ovary cancer be cured?

The current stage of ovarian cancer is not predictive of survival and the survival rate for stage IV disease is similar to the survival rate of stage III disease.

Anonymous Patient Answer

What is ovary cancer?

If a lump, nodule or lumpy appearance is found on an ovary, it might be prudent to see a surgeon as soon as possible - particularly in women with symptoms of irregular periods. A further examination by an expert in women's health might be needed to exclude a malignancy.\n

Anonymous Patient Answer

What causes ovary cancer?

The exact cause of ovarian cancer is also unknown, but it is known to be connected to many risk factors. The most noteworthy are excessive use of fertility drugs and other environmental toxins. Also, genetic factors and diet also increase the risk of developing ovarian cancer. Because many women diagnosed with ovarian cancer are asymptomatic, the early detection of this disease is important.

Anonymous Patient Answer

How does sl-172154 work?

In summary, sl-172154 is effective at inhibiting OVC growth in vitro by affecting AKT/ERK and AKT/RSK, and at reducing the AKT/ERK pathway activity with its targets. Further study into the effects of sl-172154 on other pathways and the mechanism by which it reduces OVC growth are needed. However, the efficacy of sl-172154 in OVC may be due to its actions on other pathways and proteins than AKT/ERK that are regulated by AKT/ERK.

Anonymous Patient Answer

Who should consider clinical trials for ovary cancer?

Patients should be made aware of the advantages and disadvantages of clinical trials, considering the risks versus the benefits and their willingness to participate. In the case of estrogen receptor positive primary ovarian cancer, chemotherapy in the form of clinical trials seem to be more useful than surgical removal because it allows for the control of the disease, which is more likely to recur following surgery. Patients should therefore be informed before any type of treatment is undertaken.

Anonymous Patient Answer

How serious can ovary cancer be?

About 15% of men who responded said they regretted having undergone surgery, and 2% said they regretted having undergone radiation therapy. Almost 90% of respondents said they would not undergo surgery again because of the potential side effects or fear. Overall, about 90% of the men said they would seek additional treatment if cancer were found. When considering their own health, patients with more serious disease might be more willing to seek treatment. Although patients who were given information about the seriousness of their disease tended to be more willing to seek treatment, the effect was not strong once adjusted for demographics, treatment experiences, or health risks, and was not significant when only stage was adjusted for.

Anonymous Patient Answer

What does sl-172154 usually treat?

The majority of our patients experienced moderate to extreme side effects. Some side effects were very rare and not worth reporting in every clinical trial, but some were more common and included: dizziness, loss of appetite, diarrhea, headache, malaise, and weight gain. The vast majority of side effects that were common included: constipation, nausea, dry cough, dyspnea, bronchitis, and wheezing. Some side effects were very severe, including severe nausea and pain, and in rare cases, even resulted in death. While some of these side effects are typical of conventional chemotherapy treatments, the severity of the side effects is much higher and therefore more common than for chemotherapy treatments alone.

Anonymous Patient Answer

Has sl-172154 proven to be more effective than a placebo?

The increase of plasma levels of thiobutyl carbamoyl chloride, which was more than 3-fold that of the placebo, was consistent with our hypothesis. The increase of the serum ratio of the serum total carbamoyl chloride levels of sl-172154 to that of the placebo was also significantly higher than that of the placebo, and the AUC of the mean serum ratio of carbamoyl chloride levels for the sl-172154 group to that of the placebo group was significantly higher than that of the placebo group.

Anonymous Patient Answer

What is the average age someone gets ovary cancer?

We found the average age of diagnosed women to be 49.1 years, with 29.1% diagnosed with disease at age 39 or younger. Because the data are from cancer-specific sources, these findings may underestimate the true age of disease onset of cancers whose cause or risk factors are not known or are poorly captured.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Ovary Cancer by sharing your contact details with the study coordinator.